克拉屈滨治疗24例毛细胞白血病的临床分析
回顾性分析2006年11月至2017年10月接受克拉屈滨治疗的24例毛细胞白血病患者,评估疗效与不良反应。可评估的19例患者完全缓解/不确定的完全缓解率为94.7%,总体反应率100.0%;所有患者出现2~4级血液学不良反应,均可控或自行恢复,中位随访15个月无进展、复发或死亡。
要点
- 24例患者中20例接受克拉屈滨单药、4例联合利妥昔单抗治疗。
- 可评估19例的完全缓解/不确定的完全缓解率为94.7%,总体反应率100.0%。
- 3~4级中性粒细胞减少占66.67%,3~4级血小板减少占29.2%,均可控或自行恢复。
核心结论
- 克拉屈滨治疗毛细胞白血病反应率高,不良反应可控,预后好。
研究设计与样本
- 回顾性分析2006年11月至2017年10月应用克拉屈滨治疗的24例毛细胞白血病患者的临床资料,分析疗效和不良反应。
主要发现
- 24例患者中男22例、女2例,诊断时中位年龄49.5(33~76)岁;脾大20例(轻度4例、中度4例、巨脾12例),淋巴结肿大3例,已行脾切除术1例。
- 全血细胞减少5例,2系减少15例,1系减少4例;流式细胞术检测骨髓中位毛细胞白血病细胞比例为21.79%(0.69%~68.96%);一代或二代测序检测BRAF突变阳性率75.00%(15/20)。
- 20例接受克拉屈滨单药治疗(单疗程19例、2个疗程1例),4例接受克拉屈滨联合利妥昔单抗治疗(单疗程3例、2个疗程1例)。
- 除外5例随访时间<6个月者,19例于治疗后6~12个月评估:完全缓解9例、不确定的完全缓解9例、部分缓解1例,完全缓解/不确定的完全缓解率94.7%,总体反应率100.0%。
- 中位随访15(3~133)个月,无患者发生疾病进展、复发及死亡,中位总生存和无进展生存时间均为未达到。
关键数值与推荐
- 24例患者均于克拉屈滨治疗后发生2~4级血液学不良反应,主要为3~4级中性粒细胞减少(66.67%)和3~4级血小板减少(29.2%),所有不良反应经对症处理可控或自行恢复。
- 可评估的19例患者完全缓解/不确定的完全缓解率为94.7%,总体反应率为100.0%。
临床怎么用
- 本研究提示克拉屈滨治疗毛细胞白血病反应率高、不良反应可控、预后好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the curative effect of hairy cell leukemia by clatabine. Methods: The clinical data of 24 patients with hairy cell leukemia treated by cladribine from November 2006 to October 2017 were analyzed retrospectively, then the curative effect and adverse drug reaction were analyzed. Results: ① A total of 24 patients including 22 male and 2 female, and the median age was 49.5 years (range 33 to 76) at diagnosis. There were 20 patients with of splenomegaly (4 patients with mild splenomegaly, 4 moderate splenomegaly, and 12 massive splenomegaly), 3 patients with enlargement of lymph nodes, and 1 patients who had undergone splenectomy. Five patients were pancytopenia, 15 were cytopenia in 2 lineages, and 4 patients were cytopenia only in one lineage. The median ratio of HCL cells detected by flow cytometry in bone marrow was 21.79% (0.69%-68.96%). BRAF mutation was detected in 15 patients by first generation or next generation sequencing technology. ② Among 24 patients, 20 were treated with cladribine alone (one course in 19 patients, 2 courses in 1 patient), and 4 patients were treated with cladribine combined with rituximab (one course in 3 patients, 2 courses in 1 patient). Excepting 5 patients whose follow-up time was not reaching 6 months, 19 patients were evaluated for efficacy in 6-12 months after treatment: 9 patients obtained CR, 9 obtained unconfirmed CR (Cru), the other 1 obtained PR, the CR/CRu rate was 94.7%, the overall response rate (ORR) was 100.0%. ③ All the 24 patients appeared 2-4 grade hematological adverse reactions after cladribine treatment, which were mainly grade 3/4 neutropenia (66.67%) and grade 3/4 thrombocytopenia (29.2%). All the adverse reactions were controlled or recovered spontaneously. ④ After the median follow-up time of 15 (3-133) months, no progression, recurrence or death occurred in the patients. Both median OS and PFS were not reached. Conclusion: This study suggests that treatment of HCL with cladribine has high response rate, controllable adverse reactions and the good prognosis. 目的: 探讨克拉屈滨治疗毛细胞白血病(HCL)的疗效。 方法: 回顾性分析2006年11月至2017年10月应用克拉屈滨治疗的24例HCL患者的临床资料,对其疗效和不良反应进行分析。 结果: ①24例患者中,男22例,女2例,诊断时中位年龄49.5(33~76)岁;脾大20例(轻度脾大4例,中度脾大4例,巨脾12例),淋巴结肿大3例,已行脾切除术者1例;全血细胞减少5例,2系减少15例,1系减少4例;流式细胞术检测骨髓中位HCL细胞比例为21.79%(0.69%~68.96%);一代或二代测序技术检测BRAF突变阳性率75.00%(15/20)。②24例患者中,20例接受克拉屈滨单药治疗(单疗程19例,2个疗程1例),4例接受克拉屈滨联合利妥昔单抗治疗(单疗程3例,2个疗程1例)。克拉屈滨治疗后6~12个月进行疗效评估,除外5例随访时间<6个月者,19例患者中完全缓解(CR)者9例,不确定的完全缓解(CRu)者9例,PR患者1例,CR/CRu率为94.7%,总体反应率为100.0%。③24例患者均于克拉屈滨治疗后发生2~4级血液学不良反应,主要为3~4级中性粒细胞减少(66.67%)和3~4级血小板减少(29.2%),所有不良反应经对症处理可控或自行恢复。④中位随访15(3~133)个月,无患者发生疾病进展、复发及死亡,中位总生存和无进展生存时间均为未达到。 结论: 克拉屈滨治疗HCL反应率高,不良反应可控,预后好。.
引用
- Wang TY, Li ZJ, Lyu R, et al. [Clinical analysis of 24 patients of hairy cell leukemia treated by cladribine]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30032567. doi:10.3760/cma.j.issn.0253-2727.2018.06.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。